OCTAGAM Drug Profile

Summary for Tradename: OCTAGAM

High Confidence Patents:	4
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for OCTAGAM

See drug prices for OCTAGAM

Pharmacology for OCTAGAM

Mechanism of Action	Antigen Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for OCTAGAM Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for OCTAGAM Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	10,640,548	2037-11-06	DrugPatentWatch analysis and company disclosures
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	10,646,569	2037-06-20	DrugPatentWatch analysis and company disclosures
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	11,191,833	2037-06-12	DrugPatentWatch analysis and company disclosures
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	12,233,126	2041-11-04	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for OCTAGAM Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	10,016,338	2036-12-20	Patent claims search
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	10,016,491	2035-11-09	Patent claims search
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	10,105,389	2037-03-31	Patent claims search
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	10,111,968	2036-08-10	Patent claims search
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	10,221,140	2035-08-07	Patent claims search
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	10,259,865	2037-03-15	Patent claims search
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	10,301,376	2029-03-16	Patent claims search

International Patents for OCTAGAM

Country	Patent Number	Estimated Expiration
Canada	3063324
China	109328057
Turkey	201807926
Spain	2675353
Australia	2017277757
Singapore	11202003754Y
Russian Federation	2749953

Market Dynamics and Financial Trajectory for OCTAGAM

Last updated: February 25, 2026

What is OCTAGAM?

OCTAGAM (immune globulin, human) is a plasma-derived biologic used primarily for immunoglobulin replacement therapy. It is derived from pooled human plasma and contains immunoglobulin G (IgG) antibodies. The drug is approved for primary immunodeficiency, idiopathic thrombocytopenic purpura (ITP), and other immunological conditions.

Current Market Position

OCTAGAM is among the leading IgG products, competing directly with brands like Gammagard, Privigen, and Hizentra. As of 2023, it holds approximately 15-20% of the global immunoglobulin market share.

Market Size and Growth

The global immunoglobulin market was valued at USD 11.2 billion in 2022. It is projected to reach USD 17.2 billion by 2028. The compound annual growth rate (CAGR) over this period is estimated at approximately 7.7% (Research and Markets, 2023).

Breakdown:

Year	Market Value (USD billions)	Growth Rate (%)
2022	11.2	-
2023	12.1	8.0
2024	13.0	7.4
2025	14.0	7.7
2026	15.1	7.9
2027	16.3	8.0
2028	17.2	5.5 (projected)

Key Drivers:

• Rising prevalence of immunodeficiency disorders.
• Increased adoption for autoimmune diseases.
• Broader clinical use and off-label prescribing.
• Demand in emerging markets.

Pipeline and Competitive Landscape

Several biosimilar products and plasma-derived therapies are in development, aiming to reduce costs and expand access. The market's fragmentation highlights the importance of brand loyalty and supply chain reliability.

Key Competitors:

• Gammagard (Takeda)
• Privigen (CSL Behring)
• Hizentra (CSL Behring)
• Fidaxomicin (Pfizer) - not directly competing but indicative of biologic trends.

Pricing Dynamics

The average wholesale price (AWP) for IgG therapies ranged from USD 100 to USD 250 per gram in 2023, depending on formulation and region. Prices have remained relatively stable due to manufacturing complexities and regulatory standards but face pressure from biosimilar entries.

Regulatory Environment

The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) regulate plasma-derived biologics. Post-2020, there is increased oversight to ensure safety from pathogen transmission, influencing production costs. Pricing negotiations and formulary inclusions are governed by healthcare payers, affecting reimbursement.

Supply Chain and Manufacturing

OCTAGAM's supply depends on plasma collection, which is constrained by donor availability and ethical sourcing standards. Manufacturing requires rigorous purification and viral inactivation processes, increasing operational costs.

Challenges:

• Plasma donor recruitment.
• Supply shortages during public health crises.
• Stringent quality standards raising production costs.

Financial Trajectory and Investment Outlook

OCTAGAM's revenue is linked with overall demand for immunoglobulins. For 2023, it is estimated to generate USD 250-300 million worldwide, with incremental growth driven by expanded indications and regional market penetration.

Revenue Drivers:

• Market expansion into Asia-Pacific and Latin America.
• Increased dosing for autoimmune encephalitis and neurological disorders.
• Competition resistance due to brand trust.

Risk Factors:

• Price pressure from biosimilar entries.
• Supply chain disruptions affecting availability.
• Regulatory restrictions on plasma sourcing.

Strategic Opportunities

• Diversifying indications, including emerging autoimmune diseases.
• Expanding plasma collection networks.
• Investing in manufacturing efficiencies.

Key Takeaways

• The immunoglobulin market is expanding at a CAGR of approximately 7.7%, reaching USD 17.2 billion by 2028.
• OCTAGAM holds a significant share, with sales primarily driven by demand in immunodeficiency and autoimmune indications.
• Price stability persists despite biosimilar competition, owing to manufacturing complexity and brand reputation.
• Supply chain constraints impact production reliability; growth strategies involve expanding plasma sources and streamlining manufacturing.
• Future growth hinges on approval for new indications, regional expansion, and maintaining supply chain integrity.

FAQs

1. How does OCTAGAM compare pricing-wise with competitors?

Pricing varies by region but averages USD 100-250 per gram in 2023. OCTAGAM's pricing remains competitive due to brand trust and stable supply.

2. What are the primary growth opportunities for OCTAGAM?

Expanding into autoimmune neurological disorders, entering emerging markets, and developing biosimilar versions to combat biosimilar entry.

3. What factors could hinder OCTAGAM's market growth?

Supply shortages of plasma, price pressures from biosimilar products, and regulatory restrictions on plasma sourcing.

4. How does the regulatory environment affect OCTAGAM?

Stringent safety standards increase production costs but ensure market credibility. Reimbursement policies influence sales, particularly in cost-sensitive regions.

5. What is the outlook for OCTAGAM’s revenue over the next five years?

Revenue is expected to grow modestly alongside the overall immunoglobulin market, with emphasis on expanding indications and regional presence.

---

Sources

[1] Research and Markets. (2023). Global Immunoglobulin Market Report.
[2] IQVIA. (2022). Biologic Market Trends.
[3] FDA. (2022). Guidance on plasma-derived biologics.
[4] European Medicines Agency. (2022). Regulation updates for plasma-based therapies.